enGene Holdings Inc. (ENGNW)

Market Cap	168.14M
Revenue (ttm)	n/a
Net Income (ttm)	-79.88M
Shares Out	51.11M
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.7470
Day's Range	n/a
52-Week Range	0.4152 - 2.7400
Beta	-0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 13, 2025

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Ronald H. Cooper
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGNW
• Website: https://www.engene.com